AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Chahal, H, Alband, N, Ansorge, O, Karavitaki, N, Carlsen, E, Wass, J, Grossman, AB, Korbonits, M
التنسيق:	Conference item
منشور في:	2010

مواد مشابهة

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
حسب: Chahal, H, وآخرون
منشور في: (2011)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
حسب: Chahal, H, وآخرون
منشور في: (2012)

Acromegaly: Treatment with somatostatin analogs
حسب: Karavitaki, N, وآخرون
منشور في: (2005)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
حسب: Ur, E, وآخرون
منشور في: (1992)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
حسب: Karavitaki, N, وآخرون
منشور في: (2005)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
حسب: Grozinsky-Glasberg, S, وآخرون
منشور في: (2008)

CURRENT VIEWS ON THE TREATMENT OF ACROMEGALY WITH SOMATOSTATIN ANALOGUES
حسب: I. A. Ilovaiskaya
منشور في: (2017-12-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
حسب: Jenkins, P, وآخرون
منشور في: (2000)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
حسب: Grozinsky-Glasberg, S, وآخرون
منشور في: (2008)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
حسب: George Kontogeorgos, وآخرون
منشور في: (2022-01-01)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
حسب: Sang Ouk Chin, وآخرون
منشور في: (2019-03-01)

Effects of Somatostatin Analogues on Glucose Metabolism in Acromegaly: Friend of Foe?
حسب: Corin Badiu, MD, PhD
منشور في: (2016-01-01)

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
حسب: Fernandez, A, وآخرون
منشور في: (2008)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
حسب: Cristina Alvarez-Escola, وآخرون
منشور في: (2016-11-01)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
حسب: Cecilia Follin, وآخرون
منشور في: (2016-08-01)

Antiangiogenic effects of somatostatin analogues.
حسب: García de la Torre, N, وآخرون
منشور في: (2002)

Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort.
حسب: Preda, V, وآخرون
منشور في: (2014)

Pegvisomant: a new treatment modality for acromegaly.
حسب: Karavitaki, N, وآخرون
منشور في: (2004)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
حسب: Adrian F Daly, وآخرون
منشور في: (2019-04-01)

The Pathogenic Role of AIP Mutations - The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.
حسب: Trivellin, G, وآخرون
منشور في: (2010)

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
حسب: Larkin, S, وآخرون
منشور في: (2013)

Increased population risk of AIP-related acromegaly and gigantism in Ireland.
حسب: Radian, S, وآخرون
منشور في: (2016)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
حسب: Karavitaki, N, وآخرون
منشور في: (2005)

Adherence to somatostatin analog therapy for acromegaly
حسب: I. A. Ilovayskaya
منشور في: (2021-05-01)

Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
حسب: Mehmet Muhittin Yalçın, وآخرون
منشور في: (2024-10-01)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
حسب: Ming Shen, وآخرون
منشور في: (2018-01-01)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
حسب: Lingyun Ma, وآخرون
منشور في: (2020-08-01)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
حسب: Kaltsas, G, وآخرون
منشور في: (2005)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
حسب: Ming Shen, وآخرون
منشور في: (2019-01-01)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
حسب: Rosa Maria Paragliola, وآخرون
منشور في: (2018-03-01)

The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly
حسب: Marta Araujo-Castro, وآخرون
منشور في: (2021-08-01)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
حسب: Ur, E, وآخرون
منشور في: (1993)

Evidence for the effectiveness of radiotherapy in the treatment of acromegaly.
حسب: Wass, J
منشور في: (1997)

AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
حسب: Leontiou, C, وآخرون
منشور في: (2009)

Hypercalcaemia in acromegaly is not always due to men-1
حسب: Zabuliene, L, وآخرون
منشور في: (2005)

Rathke's cleft cysts.
حسب: Trifanescu, R, وآخرون
منشور في: (2012)

Growth hormone-releasing peptides (GHRP) and their analogues
حسب: Korbonits, M, وآخرون
منشور في: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
حسب: Korbonits, M, وآخرون
منشور في: (1996)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
حسب: Joan Gil, وآخرون
منشور في: (2021-03-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
حسب: Hubina, E, وآخرون
منشور في: (2006)